GM-60106

GM-60106 is a novel, orally administered small molecule antagonist of the serotonin 5-hydroxytryptamine receptor 2A (HTR2A, also known as the serotonin 2A receptor), developed by JD Bioscience. It is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), liver fibrosis, and obesity. The drug acts peripherally—minimizing blood-brain barrier penetration—to directly inhibit HTR2A in hepatic stellate cells, thereby reducing hepatic steatosis and fibrosis without central nervous system side effects. Preclinical studies have demonstrated superior efficacy in reducing liver inflammation and fibrosis compared to other candidates, with favorable pharmacokinetics for oral dosing and a strong safety profile. As of mid-2025, GM-60106 has completed phase I trials showing good tolerability and has received FDA approval to begin phase IIa trials in MASH patients[1][2][3][4][7].